To the best of the authors’ knowledge, this is the first study that evaluated in a real-world setting the psychiatric adverse events associated with three anti-diabetic and anti-obesity GLP1 receptor agonist medications. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.